title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Literature search | The systematic literature search identified 1062 records. We used an automated tool (Rayyan) to identify duplicate records in the eligibility process of this systematic review; after eliminating duplicates, 776 records remained. The records excluded after screening by title and abstract were 766, and only ten full-text... | PMC10374120 | ||
Flow diagram of the study identification process. | PMC10374120 | |||
Study characteristics and quality assessment | UC | Four studies were included in this systematic review, three were RCTs, and one was non-RCTs. The included studies involved a total of 358 patients. The studies of Wang et al. (2013) and Yang et al. (2018) were conducted in China, Álvaro-Gracia et al. (2017) in Spain, and Shadmanfar et al. (2018) was conducted in Iran; ... | PMC10374120 | |
Risk of bias assessment of included RCTs–Cochrane RoB tool 2.0. | PMC10374120 | |||
Risk of bias assessment in the non-RCTs of Wang, 2013 –ROBINS-I tool. | PMC10374120 | |||
Overall characteristics of the included studies. | Rheumatoid Arthritis | RHEUMATOID ARTHRITIS | UC-MSCs, Umbilical Cord-derived Mesenchymal Stem Cells; DMARDs, Rheumatoid Arthritis with Disease-Modifying Drugs; Ad-MSCs, Adipose-derived Mesenchymal Stem Cells; BM-MSCs, Bone marrow-derived Mesenchymal Stem Cells; IV, Intravenous infusion; IA, Intra-articular injection. | PMC10374120 |
GRADE assessment | pain | ADVERSE EVENTS, ADVERSE EVENT | We use the GRADE approach to assess evidence for each important outcome and present the summary findings for all combinations of MSCs therapy and control interventions in the included RCTs and non-RCTs. These treatments were evaluated as clinical activity, measures of response by the ACR scale, and safety of therapy wi... | PMC10374120 |
GRADE assessment. | Rheumatoid Arthritis, Osteoarthritis | RHEUMATOID ARTHRITIS, DISEASE, OSTEOARTHRITIS | UC-MSCs, Umbilical Cord-derived Mesenchymal Stem Cells; Ad-MSCs, Adipose-derived Mesenchymal Stem Cells; BM-MSCs, Bone marrow-derived Mesenchymal Stem Cells; DMARDs, Rheumatoid Arthritis with Disease-Modifying Drugs; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; VAS, Visual Analogue Scale; DAS2... | PMC10374120 |
Outcomes | PMC10374120 | |||
Safety evaluation | ADVERSE EVENTS | Overall, MSCs therapy was safe and well tolerated in all studies, as no serious adverse events (non-SAEs) were observed during or after MSCs administration. Wang et al. [ | PMC10374120 | |
Forest Plot of the incidence of adverse events in the MSCs therapy group and control group. | PMC10374120 | |||
Forest Plot of the incidence of non-serious adverse events in MSCs therapy group and control group. | PMC10374120 | |||
Forest Plot of the incidence of serious adverse events in MSCs therapy group and control group. | ADVERSE EVENTS | In the L’Abbé plot for the rate of adverse events ( | PMC10374120 | |
L’Abbé plot for the incidence of adverse events in the MSCs therapy group and control group. | deaths, gastrointestinal tract bleeding | MALIGNANCIES | Decreased total protein and globulin levels and increased albumin and hemoglobin levels after DMARDs plus UC-MSCs administration in comparison with the control group had shown in the study of Wang et al.; the function of the liver could be estimated based on this elevation in levels of albumin and hemoglobin and based ... | PMC10374120 |
Sensitivity analyses | The small number of RCTs in each safety meta-analysis made it impossible the conduct sensitivity analyses. | PMC10374120 | ||
Publication bias | Publication bias was evaluated at the outcome level with the funnel plot ( | PMC10374120 | ||
Funnel plot, using data from 3 trials of adverse events in MSCs therapy group and control group. | PMC10374120 | |||
Summary of active RA clinical trials with MSC therapy that included a control group. | PMC10374120 | |||
Discussion | rheumatoid arthritis, tumor necrosis, TNF-α, toxicity, swollen joints, inflammation, UC, pain, RA | RHEUMATOID ARTHRITIS, TUMOR NECROSIS, ADVERSE EVENTS, INFLAMMATION, INFLAMMATORY DISEASE | Mesenchymal stem cell (MSC) therapies have been used as cell-based treatments during the last decades, owing to their potential applications such as anti-inflammatory, uncommon immunomodulatory competence, self-renewal, and multipotency properties. Many ongoing clinical trials are investigating the safety and efficacy ... | PMC10374120 |
Conclusion | RA | EVENTS | The evidence of effect is inconclusive for the efficacy outcomes, although the data showed a trend toward clinical efficacy. Our findings could suggest that MSCs therapy could be considered in treating RA when first-line treatment of RA as conventional synthetic disease-modifying anti-rheumatic drugs (cs-DMARDs) treatm... | PMC10374120 |
Supporting information | PMC10374120 | |||
PRISMA 2020 checklist. | (DOCX)Click here for additional data file. | PMC10374120 | ||
Search strategies for each database. | (DOCX)Click here for additional data file.We want to thank BioXcellerator, BioXscience, and BioXtech for their administrative assistance and critical review of the manuscript. | PMC10374120 | ||
References | PMC10374120 | |||
Introduction | COVID-19Tetracyclines, coronavirus disease 2019 | VIRUS, CORONAVIRUS DISEASE 2019 | Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, the development of vaccines and therapeutic agents has mitigated its severity and mortality. mRNA vaccines, such as BNT162b2 and mRNA-1273In addition to vaccines, antiviral agents, and neutralizing antibodies, which are specific to the SARS-CoV-2 v... | PMC10447520 |
Results | PMC10447520 | |||
Disposition of patients | This open-label, multicenter, parallel-group, randomized controlled trial was conducted between September 1, 2020 and March 31, 2022 at four institutes in Osaka, Japan. The last entry was on September 22, 2021, when the delta variant of SARS-CoV-2 was prevalent in Japan. Twenty-three hospitalized patients who provided ... | PMC10447520 | ||
Baseline characteristics of patients | The baseline characteristics of the 20 patients in the mITT population were similar across groups (Table Baseline clinical characteristics (mITT population).mITT: modified intention-to-treat. | PMC10447520 | ||
Preventing the exacerbation of COVID-19 | respiratory failure, exacerbations | RESPIRATORY FAILURE | Kaplan–Meier estimates of the cumulative incidence of dexamethasone treatment due to COVID-19 exacerbations by day 8 were 42.9% in the control group (95% CI 7.6% to 75.7%), 14.3% in the demeclocycline 150 mg group (95% CI 0.5% to 49.1%), and 40.0% in the demeclocycline 300 mg group (95% CI 3.1% to 78.6%) (Fig. (Kaplan–... | PMC10447520 |
SARS-CoV-2 viral RNA level | Saliva SARS-CoV-2 RNA turned negative on day 8 in 42.9% (3/7) of patients in the demeclocycline 150 mg group and 50.0% (2/4) in the demeclocycline 300 mg group, in contrast to only 16.7% (1/6) in the control group (as shown in Table | PMC10447520 | ||
T cell and cytokine responses after treatment | BLOOD | T cell and cytokine responses were analyzed from blood samples collected at baseline (prior to the study treatment on day 1) and on day 8. Blood samples collected on day 8 were obtained prior to the administration of dexamethasone, if applicable. Due to the administration of dexamethasone prior to blood sample collecti... | PMC10447520 | |
B cell and antibody responses after treatment | The average change rates of CD19At the initiation of the study treatment, SARS-CoV-2 antibodies in three patients were positive. The durations from symptom onset to the initiation of the study treatment for these patients were seven, eleven, and thirteen days, respectively. Among patients whose antibodies were negative... | PMC10447520 | ||
COVID-19 symptoms | cough | On day 1, the most prevalent symptom among each group was cough, with a prevalence of 57.1% (4/7) in the control group, 71.4% (5/7) in the demeclocycline 150 mg group, and 83.3% (5/6) in the demeclocycline 300 mg group (as shown in Supplementary Fig. | PMC10447520 | |
Safety | ADVERSE EVENTS, ADVERSE EVENT | Treatment-emergent adverse events (TEAEs) were reported by one (14.3%), one (14.3%), and three (50.0%) patients in the control, demeclocycline 150 mg, and demeclocycline 300 mg groups, respectively (as shown in Table Adverse events (safety analysis population) over 29 days. | PMC10447520 | |
Discussion | diabetes mellitus, hypertension, pneumonia, Hypertension | PNEUMONIA, DISEASE, DIABETES MELLITUS, HYPERTENSION, HYPERTENSION | In the present study, the administration of low-dose demeclocycline for patients with mild-to-moderate COVID-19 was well tolerated and demonstrated potential in mitigating the exacerbation of COVID-19. The number of CD4Patients with mild-to-moderate COVID-19 were recruited in the present study. Immunological responses ... | PMC10447520 |
Methods | PMC10447520 | |||
Study design | The present study was an open-label, multicenter, parallel-group, randomized controlled clinical trial involving patients diagnosed with mild-to-moderate COVID-19. Participants with mild-to-moderate COVID-19 were planned to be randomly assigned in a 1:1:1 ratio to one of three groups: a control group (normal treatment)... | PMC10447520 | ||
Patients | SARS-CoV-2 infection | SARS-COV-2 INFECTION | We prospectively identified patients aged between 20 and 75 years with SARS-CoV-2 infection confirmed by a positive reverse transcription-polymerase chain reaction (RT-PCR) or SARS-CoV-2 antigen tests that were approved by the Ministry of Health, Labour and Welfare in Japan. Inclusion criteria were mild-to-moderate COV... | PMC10447520 |
Treatment | Patients in the demeclocycline 150 mg daily group and demeclocycline 300 mg daily group (administered as 150 mg twice daily) received the study drug orally in the form of demeclocycline 150 mg capsules for a period of 14 days. The concurrent use of corticosteroids, including dexamethasone, immunosuppressants, and immun... | PMC10447520 | ||
Randomization | The patients were randomly assigned to one of three groups; control, demeclocycline 150 mg daily, demeclocycline 300 mg daily groups. The allocation ratio was set at 1:1:1. We used stratified randomization by institute with permuted blocks (block size = 3). In this study, an open-label design was applied. The reason fo... | PMC10447520 | ||
Outcomes and assessments | SECONDARY | The primary and secondary outcomes of the present study included changes from baseline (day 1, prior to the study treatment) in T cells, cytokines, and SARS-CoV-2 RNA on day 8. The primary outcome was the change rate of peripheral CD8Clinical outcomes included the change in oxygen saturation measured by pulse oximetry ... | PMC10447520 | |
Sample size and statistical analyses | ADVERSE EVENTS, SECONDARY | We estimated that 8 patients were needed in each group to detect a 15% difference in the change rate of CD8Efficacy analyses were performed on the mITT population, where patients without receiving the study treatment at any time, without any observations on efficacy/safety, or with eligibility violations were excluded ... | PMC10447520 | |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-41051-2. | PMC10447520 | ||
Acknowledgements | This work was funded by Shionogi & Co., Ltd., Strategic Global Partnership & X (Cross)- Innovation Initiative, Graduate School of Medicine, Osaka University and Osaka University Hospital, Grant for Research and Development against Covid-19, and JSPS KAKENHI Grant Number 21K08153 (KI). The clinical study was supported b... | PMC10447520 | ||
Author contributions | T.M. | K.I. and H.K. conceptualized the study. K.I., H.K., and T.Y. were involved in finalizing the protocol of the study. T.N., N.Y., T.K., K.H., T.M., K.T., K.M., A.O., S.G., K.A., M.M., and H.K. were involved in the clinical care of patients. S.O. and T.Y. were involved in data curation and the formal analysis of data. Y.T... | PMC10447520 | |
Data availability | The authors declare that the primary data supporting the results of the present study are available within the article and its supplementary information files. Additional data may be obtained from the corresponding author upon reasonable request. | PMC10447520 | ||
Competing interests | The authors declare no competing interests. | PMC10447520 | ||
References | PMC10447520 | |||
Abstract | PMC10417098 | |||
Background | lung cancer, NSCLC, skin toxicity | LUNG CANCER, SKIN TOXICITIES, SKIN TOXICITY, NSCLC | Dacomitinib significantly improves progression‐free survival and overall survival (OS) compared with gefitinib in patients with non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations. However, dacomitinib often causes skin toxicities, resulting in treatment discontinua... | PMC10417098 |
Methods | NSCLC, skin toxicity | SKIN TOXICITY, NSCLC | We performed a single‐arm, prospective, open‐label, multi‐institutional phase II trial for comprehensive skin toxicity prophylaxis. Patients with NSCLC harboring EGFR‐activating mutations were enrolled and received dacomitinib with comprehensive prophylaxis. The primary endpoint was the incidence of skin toxicity (Grad... | PMC10417098 |
Results | L858R, Skin toxicities, paronychia, rash | MAY, PARONYCHIA, SKIN TOXICITY, SKIN TOXICITIES | In total, 41 Japanese patients participated between May 2019 and April 2021 from 14 institutions (median age 70 years; range: 32–83 years), 20 were male, and 36 had a performance status of 0–1. Nineteen patients had exon 19 deletions and L858R mutation. More than 90% of patients were perfectly compliant with prophylact... | PMC10417098 |
Conclusion | SKIN TOXICITY | Although the prophylactic strategy was ineffective, the adherence to prophylactic medication was quite good. Patient education regarding prophylaxis is important and can lead to improved treatment continuity.We evaluated whether comprehensive prophylaxis reduces dacomitinib‐induced skin toxicity and improves treatment ... | PMC10417098 | |
INTRODUCTION | lung cancer, NSCLC | LUNG CANCER, SKIN TOXICITY, NSCLC | The current standard of care for patients with advanced or metastatic non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations is treatment with EGFR‐tyrosine kinase inhibitors (TKIs). A meta‐analysis of randomized controlled trials with first‐generation EGFR‐TKIs (gefit... | PMC10417098 |
METHODS | PMC10417098 | |||
Study design and patient selection | SQUAMOUS CELL CARCINOMA, BRAIN METASTASES, ONCOLOGY, RECURRENT NSCLC, INTERSTITIAL LUNG DISEASE | This multi‐institutional phase II trial employed a single‐arm, prospective, and open‐label design. The study protocol has been previously reported and registered in the Japan Registry of Clinical Trials (jRCTs071190015, Figure The key eligibility criteria were as follows: patients with advanced or recurrent NSCLC exclu... | PMC10417098 | |
Treatments | NSCLC, toxicities, diarrhea, Cancer | ADVERSE EVENT, DISEASE PROGRESSION, ADVERSE EVENTS, INTERSTITIAL PNEUMONITIS, SKIN TOXICITIES, NSCLC, EVENTS, SKIN TOXICITY, CANCER | Patients can participate in the study regardless of prior treatment for NSCLC. If the patients have received prior therapy, the following periods must have elapsed before study entry and adverse events: at least 2 weeks after cytotoxic chemotherapy administration and 4 weeks after chest irradiation. If the patient rece... | PMC10417098 |
Endpoints | toxicity, rash, pruritus, paronychia, palmar‐plantar erythrondysesthesia syndrome, eczema | SKIN INFECTION, PARONYCHIA, ERYTHEMA MULTIFORME, SKIN TOXICITIES, ECZEMA | The primary endpoint was the incidence of skin toxicities ranked as Grade ≥2 during the initial 8 weeks of dacomitinib treatment. Dermatologic toxicity was defined as acneiform rash, dry skin, pruritus, paronychia, palmar‐plantar erythrondysesthesia syndrome, maculopapular rash, erythema multiforme, skin infection, and... | PMC10417098 |
Statistical analysis | NSCLC, skin toxicity, skin toxicities | SKIN TOXICITIES, SKIN TOXICITY, NSCLC | We planned to include 40 patients with NSCLC in this trial. The sample size was calculated using a one‐sample binomial test. In the ARCHER1042 trial, the incidence of Grade ≥2 skin toxicity during 8 weeks of dacomitinib initiation was 46% in the placebo group and 23% in the doxycycline prophylaxis group, respectively.R... | PMC10417098 |
Ethics considerations | This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol and all amendments were reviewed and approved by the ethical review board of the Clinical Research Network Fukuoka Certified Review Board (CRB7180004). All patients provided written informed consent before enro... | PMC10417098 | ||
RESULTS | PMC10417098 | |||
Patients | NSCLC | MAY, NEUROENDOCRINE CARCINOMA, NSCLC | A total of 41 patients with EGFR‐mutated NSCLC were enrolled between May 2019 and April 2021 from 14 institutions. The data cut‐off date was April 30, 2022. The baseline patient characteristics are summarized in Table Baseline patient characteristics (Abbreviations: EGFR, epidermal growth factor receptor; LCNEC, large‐... | PMC10417098 |
Medication adherence | Of the 41 enrolled patients, more than 90% were perfectly compliant with prophylactic minocycline administration throughout the study period. Adherence to the topical medications was lower than that to the oral prophylaxis; nevertheless, more than 80% of the patients were compliant with the topical medications (skin mo... | PMC10417098 | ||
Primary endpoint | toxicities, Skin toxicities | SKIN | Skin toxicities (Grade ≥2) occurred in 43.9% (90% CI, 31.2%–56.7%) of the enrolled patients during the initial 8 weeks of dacomitinib therapy, which did not meet the primary endpoint (Skin toxicities in the initial 8 weeks of treatment ( | PMC10417098 |
Dacomitinib treatment in the initial 8 weeks | DISEASE PROGRESSION | During the 8 weeks after the start of dacomitinib therapy, nine patients (22.2%) discontinued treatment with dacomitinib. Disease progression was the most common cause (five patients). Among the patients who discontinued dacomitinib within the 8 weeks, the median treatment duration was 22 days (range: 8–52 days) (Table... | PMC10417098 | |
Dose modification and safety | acneiform rash, paronychia, rash, skin toxicities | ADVERSE EVENTS, ADVERSE EVENT, PARONYCHIA, SKIN TOXICITIES | Due to skin toxicities, eight patients (19.5%; 95% CI, 7.4%–31.6%) underwent dose reduction. Of the eight patients, seven reduced the dacomitinib dosage once and one reduced the dose twice. The reasons for dose reduction mainly included acneiform rash (six patients), maculopapular rash (three patients), and paronychia ... | PMC10417098 |
Efficacy and long‐term safety | The median PFS was 6.8 months (95% CI, 4.0–8.6 months) and median OS was 21.6 months (95% CI, 17.0 months to not reached) (Figures Progression‐free survival after enrollment in the study. The median progression‐free survival time was 6.8 months and median follow‐up time was 6.2 months.Overall survival after enrollment ... | PMC10417098 | ||
DISCUSSION | toxicity, infections, rash, paronychia, keratinization, skin toxicities, cutaneous toxicity, skin toxicity | SKIN, INFECTIONS, PARONYCHIA, SKIN TOXICITIES, SKIN TOXICITY | This was a prospective interventional study with prophylactic treatment to reduce skin toxicity associated with dacomitinib treatment. A total of 41 patients participated, and skin toxicities of Grade ≥2 were observed in 18/41 patients (43.9%; 90% CI, 31.2%–56.7%) during the initial 8 weeks of treatment. The primary en... | PMC10417098 |
AUTHOR CONTRIBUTIONS | PMC10417098 | |||
FUNDING INFORMATION | This research was funded by Pfizer. Inc. | PMC10417098 | ||
CONFLICT OF INTEREST STATEMENT | Tadaaki | Shigeru Tanzawa recieved personal fees as honoraria from Astrazeneca K.K, Lily Japan, Chugai Pharmaceutical and Taiho Pharmaceutical. Tadaaki Yamada recieved commercial research grants from Pfizer, Ono Pharmaceutical, Janssen Pharmaceutical K.K, AstraZeneca, and Takeda Pharmaceutical Company Limited, payment for lectur... | PMC10417098 | |
ETHICAL APPROVAL | This study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol and all amendments were reviewed and approved by the ethical review board of the Clinical Research Network Fukuoka Certified Review Board (CRB7180004). All patients provided written informed consent before enro... | PMC10417098 | ||
CLINICAL TRIAL REGISTRATION | The study protocol has been previously reported and registered in the Japan Registry of Clinical Trials (jRCTs071190015). | PMC10417098 | ||
Supporting information |
Figure S1.
Click here for additional data file.
Table S1.
Click here for additional data file. | PMC10417098 | ||
ACKNOWLEDGMENTS | We thank the patients who participated in this study and their families and site staff. We also thank the contributors of this study (Nobuhiko Seki, Noriyuki Ebi, Kohei Yoshimine, Masafumi Yamaguchi, Takashi Yokoi, Kazutoshi Komiya, Kazuo Kasahara, Akira Nakao, and Shinsuke Shiotsu) and the Clinical Research Support Ce... | PMC10417098 | ||
DATA AVAILABILITY STATEMENT | The datasets analyzed during the current study are available from the corresponding author on reasonable request. | PMC10417098 | ||
REFERENCES | PMC10417098 | |||
Abstract | PMC10469755 | |||
Background | cancer | CANCER | Most physical activity (PA) interventions in young adult cancer survivors (YACS) have focused on short‐term outcomes without evaluating longer‐term outcomes and PA maintenance. This study examined the effects of an mHealth PA intervention at 12 months, after 6 months of tapered contacts, relative to a self‐help group a... | PMC10469755 |
Methods | sedentary behaviors | YACS participated in a 12‐month randomized trial that compared self‐help and intervention groups. All participants received an activity tracker, smart scale, individual videochat session, and access to a condition‐specific Facebook group. Intervention participants also received lessons, tailored feedback, adaptive goal... | PMC10469755 | |
Results | From baseline to 12 months, there were no between‐ or within‐group differences in accelerometer‐measured total PA min/week, while increases in self‐reported total PA were greater in the intervention versus self‐help group (mean difference = +55.8 min/week [95% CI, 6.0–105.6], | PMC10469755 | ||
Conclusion | cancer, Cancer | CANCER, CANCER | The intervention was not more effective than the self‐help group at increasing accelerometer‐measured total PA over 12 months. Both groups maintained PA from 6 to 12 months. Digital approaches have potential for promoting sustained PA participation in YACS, but additional research is needed to identify what strategies ... | PMC10469755 |
INTRODUCTION | cancer | CANCER, CHRONIC DISEASE | Young adult cancer survivors (YACS), diagnosed between ages 18–39, are at increased risk for morbidity and developing chronic disease,Previous digital PA interventions have shown potential among YACS, but most studies are limited by small sample sizes and short duration (8–12 weeks).We recently completed the IMPACT tri... | PMC10469755 |
METHODS | PMC10469755 | |||
Study Design | sedentary behaviors | SECONDARY | The IMPACT trial was a 12‐month, 2‐arm randomized controlled trial of an mHealth intervention designed specifically for YACS compared with a self‐help condition. The study protocol and primary (total PA) and secondary (MVPA, light PA, steps, sedentary behaviors) outcomes at 6 months (primary time point) have been previ... | PMC10469755 |
Participants and Sample | RECRUITMENT | Participants were YACS, ages 18–39, who were post‐treatment, within 10 years of diagnosis, and not meeting PA recommendations of ≥150 min/week of MVPA (as measured by accelerometer). Details on participant recruitment and the study sample ( | PMC10469755 | |
Procedures and study conditions | The intervention and self‐help conditions have been previously described in detail. | PMC10469755 | ||
Active intervention delivery to the intervention group occurred during months 1–6, with tapered contacts from months 7–12. Intervention components were designed using social cognitive theory | PMC10469755 | |||
Self‐help | Along with the initial videochat session, self‐help participants had continued access to the digital tools for the duration of the study (i.e., months 1–12), including the condition‐specific Facebook group. Throughout months 1–12, study interventionists monitored Facebook group activity and posted when new cohorts of p... | PMC10469755 | ||
Measures | PA was measured at baseline, 6, and 12 months using accelerometers (ActiGraph GT3X+, Pensacola, FL) and self‐reported with a modified version of the Godin Leisure Time Exercise Questionnaire, | PMC10469755 | ||
Statistical analyses | sedentary behaviors | EVENTS | Descriptive analyses were conducted to summarize participants' baseline characteristics by condition. Fisher's exact tests compared the groups on reported medical events. Wilcoxon rank sum tests compared the groups on days of activity tracking and Facebook engagement. To evaluate intervention effects relative to the se... | PMC10469755 |
RESULTS | PMC10469755 | |||
Participant characteristics and adherence | Of 280 participants randomized, 242 completed accelerometer assessments (86.4%) at 12 months, of which 236 (84.3%) provided valid accelerometer data (6 malfunctioning accelerometers); 246 (87.9%) completed valid self‐report PA questionnaires (Figure Consolidated standards of reporting trials diagram of participant flow... | PMC10469755 | ||
Total physical activity | Table Changes in physical activity and sedentary behavior within and between intervention and self‐help groups in the IMPACT Trial.Abbreviations: CI, confidence interval; PA, physical activity; SD, standard deviation.Unadjusted means. Baseline sample: Adjusted for education, time since diagnosis, age, and wear time (ac... | PMC10469755 | ||
Moderate‐to‐vigorous physical activity ( | Over 12 months, both groups increased accelerometer‐measured MVPA (+22.5 min/week; 95% CI, 8.76–36.2 in intervention vs. +13.9 min/week, 95% CI, 2.97–24.9 in self‐help), with no between‐group difference (Changes in accelerometer‐measured and self‐reported moderate‐to‐vigorous physical activity by group over 12 months. ... | PMC10469755 | ||
Light physical activity, steps, and sedentary behavior | From baseline to 12 months, there were no between‐ or within‐group differences in accelerometer‐measured light PA (There were no between‐group (Analyses with participants who completed measures at all time points yielded similar results. When removing outliers in models of accelerometer‐measured total PA, between‐group... | PMC10469755 | ||
DISCUSSION | theory‐based, cancer | CANCER, RECRUITMENT, ADVERSE EFFECTS | While PA is well‐recognized as beneficial for cancer survivors, little research has examined longer‐term PA change and maintenance among YACS. The IMPACT intervention offered a mobile PA intervention to YACS who are at risk for adverse effects from cancer decades following their treatment. Following a 6‐month active in... | PMC10469755 |
AUTHOR CONTRIBUTIONS | PMC10469755 | |||
FUNDING INFORMATION | Diabetes, Digestive, Cancer | KIDNEY DISEASES, DIABETES, CANCER | National Cancer Institute (R01CA204965; P30CA016086); National Institute of Diabetes and Digestive and Kidney Diseases (P30DK056350); University of North Carolina at Chapel Hill (University Cancer Research Fund); National Center for Advancing Translational Sciences (UL1TR002489). | PMC10469755 |
CONFLICT OF INTEREST STATEMENT | None. | PMC10469755 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.